GLS and early-onset autosomal dominant Alzheimer disease: JHU083, a glutaminase inhibitor, was reported to attenuate behavioral deficits and improve disease outcomes in some neuroinflammation models, such as chronic social defeat stress and Alzheimer's disease (Hollinger et al., 2020; Zhu et al., 2019).